Pusey Leigh Ann
Known title: DirectorCIK: 0001708919
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
W.R. Berkley Eyes Earnings Beat in Q3. W.R. Berkley is expected to post a Q3 earnings beat, with analysts highlighting key metrics such as reserve gains and investment income. The company’s performance is being closely watched as part of the broader insurance earnings season. Investors are noting the firm’s solid fundamentals, including a trailing P/E of 14.3 and a dividend yield of 0.54%.
Transaction History
| LLY | ▲ Buy | Grant | 3,681 | $1.3M | 2/10/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,154 | $0 | 2/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,438 | $495K | 2/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 5,309 | $1.3M | 2/9/2022 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 2,010 | $493K | 2/1/2022 | View on chart |
| LLY | ▲ Buy | Option Exercise | 4,416 | $0 | 2/1/2022 | View on chart |
| WRB | ▲ Buy | Option Exercise | 2,547 | — | 12/1/2021 | View on chart |
| WRB | ▼ Sell | Other | 2,547 | $198K | 12/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.